Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today?

Intensity Therapeutics Inc INTS announced that safety, tolerability, efficacy, and immune activation data from its Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented during the 2023 San Antonio Breast Cancer Symposium.

The INVINCIBLE Phase 2 trial of INT230-6 demonstrated a high order of necrosis (death of tumor tissue) in presurgical breast cancer tumors in the period from diagnosis to surgery, with some patients in the Phase 2 study experiencing greater than 95% necrosis of the tumor. 

A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation, and inflammatory response. 

Further, INT230-6 treated patients experienced differential gene expression with increased median clonal diversity compared to baseline and significant changes in the immune cell composition, including CD4 T-cell and NK cells.

Data show that INT230-6 has a favorable safety profile and is well tolerated. Over 95% of treatment-emergent adverse events were low-grade 1 or 2, primarily localized pain, fatigue, and nausea.

Price Action: INTS shares are up 150% at $10.00 on the last check Friday.